📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-07-28 20:09
570 analysed today
570
Today
133,459
All-time analysed
40,112
Positive
6,281
Negative
79,251
Neutral
7,747
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
20 announcements match the current filters (relevance ≥ 5).
Sanofi Consumer Q2 Net Profit Up 13% to ₹68.8 Cr; Domestic Sales Grow 12%
Sanofi Consumer Healthcare India (SCHIL) reported a 7% YoY revenue growth to ₹235.7 cr for Q2 2026, driven by a strong 12% increase in domestic sales following product relaunches. Net profit for the quarter rose 13.3% to ₹68.8 cr, while Profit Before Tax (PBT) grew 16% YoY to ₹91.9 cr. The first half of 2026 (H1) shows stronger momentum with revenue up 18% and PBT up 25% YoY. The company maintains a robust liquidity position with cash and bank balances of ₹490.2 cr as of June 30, 2026.
Confidence: HIGH
What changedThe company has successfully transitioned into a standalone entity post-demerger, showing consistent double-digit domestic growth and brand recovery.
Why it mattersThe results validate the 'India for India' strategy and the resilience of core brands like Allegra and Combiflam after historical product recall challenges.
Q2 Revenue: ₹2,357 millionQ2 Net Profit: ₹688 millionDomestic Sales Growth (Q2): 12%PBT Margin (Q2): 39%Cash and Bank Balances: ₹4,902 million
📅 Short termThe stock may see positive sentiment as PBT growth (16%) outpaced revenue growth (7%), indicating healthy margin management.
📈 Long termThe structural shift to a specialized consumer healthcare entity allows for better focus on OTC categories; H1 growth of 18% suggests a strong trajectory.
⚠ Risk flags
- Export volatility (-9% in Q2)
- Regulatory risks regarding OTC drug classifications
- Concentration in consumer healthcare segment
Key Highlights
Revenue from operations grew 7% YoY to ₹2,357 million in Q2 2026.
Domestic sales increased by 12% YoY, benefiting from the successful relaunch of previously recalled products.
Profit Before Tax (PBT) rose 16% YoY to ₹919 million, reflecting improved operational efficiency.
H1 2026 revenue reached ₹4,649 million, a significant 18% growth over the previous year's half-yearly performance.
Cash and cash equivalents increased to ₹4,902 million from ₹3,748 million in December 2025.
👀 What to Watch
Investors should monitor the sustainability of the 12% domestic growth as the 'relaunch' impact normalizes and track the recovery of export sales, which declined 9% this quarter due to a high base.
13% Net Profit Growth in Q2 2026; Domestic Sales Up 12% YoY on Product Relaunches
Sanofi Consumer Healthcare India (SCHIL) reported a 7% YoY increase in revenue to ₹235.7 Cr for the quarter ended June 30, 2026. Net profit grew by 13.3% to ₹68.8 Cr, while Profit Before Tax (PBT) rose 16% to ₹91.9 Cr. Growth was primarily driven by the domestic market, which saw a 12% increase following the successful relaunch of previously recalled products. Despite a 9% dip in quarterly exports due to a high base, the half-year (H1) performance remains robust with total revenue up 18% and PBT up 25%.
Confidence: HIGH
What changedThe company has successfully transitioned into a standalone entity post-demerger, showing consistent growth and recovery of market share for its core brands like Allegra and Combiflam.
Why it mattersThe results validate the 'India for India' strategy and the company's ability to recover from product recalls, maintaining high operating margins (PBT margin at ~39% for the quarter).
Revenue (Q2 2026): ₹235.7 CrNet Profit (Q2 2026): ₹68.8 CrDomestic Sales Growth: 12%H1 Revenue Growth: 18%Cash Balance: ₹490.2 CrEPS (Q2 2026): ₹29.87
📅 Short termThe stock may see positive sentiment in the short term due to healthy profit growth and strong domestic performance despite export headwinds.
📈 Long termAs a specialized consumer healthcare player, the company is well-positioned to benefit from the growing self-care market in India, provided it manages regulatory risks effectively.
⚠ Risk flags
- Export volatility (9% decline in Q2)
- Regulatory shifts in OTC drug classifications
- Concentration in specific therapeutic areas like Allergy and Pain Care
Key Highlights
Revenue from operations grew 7% YoY to ₹235.7 Cr in Q2 2026.
Domestic sales increased by 12% YoY, aided by the re-establishment of key brands in the market.
Profit Before Tax (PBT) reached ₹91.9 Cr, a 16% increase over the same quarter last year.
Half-year (H1) revenue reached ₹464.9 Cr, representing an 18% growth compared to H1 2025.
Cash and cash equivalents significantly increased to ₹490.2 Cr as of June 30, 2026, from ₹374.8 Cr in December 2025.
👀 What to Watch
Investors should monitor the sustainability of the 12% domestic growth rate and watch for any regulatory updates regarding OTC drug classifications in India, which could impact distribution.
Rs 75 Dividend Approved; Sanofi Consumer Healthcare Shareholders Pass All AGM Resolutions
Sanofi Consumer Healthcare India Limited (SCHIL) has concluded its 3rd Annual General Meeting, with shareholders approving all proposed resolutions. A significant final dividend of Rs 75 per equity share for the financial year ended December 31, 2025, was ratified. While all resolutions passed, the appointment of Price Waterhouse & Co as Statutory Auditors saw notable institutional dissent at 42.72%, though it passed with an overall 91.27% majority. The company remains focused on its 'India for India' strategy following the global Opella group restructuring.
Confidence: HIGH
What changedShareholders have formally ratified the FY2025 financial statements, the Rs 75 per share dividend, and the appointment of new Statutory Auditors.
Why it mattersThis ensures corporate governance continuity and confirms the cash distribution to shareholders, reflecting the company's ability to maintain high payouts despite a slight margin compression in CY2024.
Final Dividend: Rs 75 per shareTotal Shareholders: 49,698Institutional Dissent (Res 4): 42.72%Overall Voting Majority: 91.27%Promoter Votes: 16,414,217
📅 Short termThe stock may see routine price adjustments around the dividend record and payment dates; no major immediate volatility is expected from these results.
📈 Long termLimited structural impact as the meeting was routine, but the high dividend payout confirms the business remains a strong cash generator for the parent group.
⚠ Risk flags
- Significant institutional dissent (42.72%) on the appointment of statutory auditors
Key Highlights
Approved a final dividend of Rs 75 per equity share for the financial year ended December 31, 2025
Total of 49,698 shareholders were on record for the meeting held on June 26, 2026
Resolution to appoint Price Waterhouse & Co as Statutory Auditors passed with a 91.27% overall majority
Institutional investors cast 1,799,851 votes (42.72%) against the appointment of Statutory Auditors in Resolution 4
Promoter group, holding 16,414,217 shares, voted 100% in favor of all six resolutions
👀 What to Watch
Investors should monitor the dividend credit timeline and watch for the next quarterly results to verify if the 13% expected growth rate is being met through the 'India for India' strategy.
Sanofi Consumer Healthcare India Approves Rs 75 Dividend at 3rd AGM
Sanofi Consumer Healthcare India Limited (SANOFICONR) successfully conducted its 3rd Annual General Meeting on June 26, 2026. A key outcome was the approval of a substantial final dividend of Rs. 75 per equity share for the financial year ended December 31, 2025. The company also confirmed the appointment of Price Waterhouse & Co as statutory auditors and re-appointed Mr. Stanislas Camart as a Director. Management addressed shareholder queries regarding the company's 2025 financial performance and future strategic initiatives.
Key Highlights
Approval of a final dividend of Rs. 75 per equity share of face value Rs. 10 for FY2025
Adoption of audited standalone financial statements for the year ended December 31, 2025
Appointment of M/s. Price Waterhouse & Co Chartered Accountants LLP as Statutory Auditors
Re-appointment of Mr. Stanislas Camart as Director following his retirement by rotation
Management provided a strategic overview of business performance and key developments to shareholders
👀 What to Watch
Investors should track the record date for the Rs. 75 dividend to ensure eligibility for this high-yield payout. The company's ability to maintain such dividends should be monitored alongside its standalone growth performance.
Sanofi Consumer Healthcare India to Hold 3rd AGM; Proposes ₹75 Final Dividend
Sanofi Consumer Healthcare India Limited (SANOFICONR) has scheduled its 3rd Annual General Meeting for June 26, 2026. The Board has recommended a substantial final dividend of ₹75 per equity share for the financial year ended December 31, 2025. The record date for dividend eligibility is June 19, 2026, with the payment scheduled for July 9, 2026. Other key agenda items include the appointment of Price Waterhouse & Co as Statutory Auditors for a five-year term.
Key Highlights
Recommended a final dividend of ₹75 per equity share of ₹10 each for FY 2025.
3rd Annual General Meeting (AGM) scheduled for June 26, 2026, via Video Conferencing.
Record date for dividend entitlement is June 19, 2026; payout date is July 9, 2026.
Proposed appointment of Price Waterhouse & Co Chartered Accountants LLP as Statutory Auditors for 5 years.
Ratification of ₹3,15,000 remuneration for Cost Auditors M/s. Kishore Bhatia & Associates for FY 2026.
👀 What to Watch
Investors should ensure their bank details and tax residency documents are updated with the RTA by June 19, 2026, to receive the ₹75 dividend. The high dividend payout reflects strong cash flow and shareholder focus.
Sanofi Consumer Healthcare Sets June 19, 2026, as Record Date for Final Dividend
Sanofi Consumer Healthcare India Limited has announced the timeline for its final dividend for the financial year 2025. The company has fixed June 19, 2026, as the record date to determine shareholder eligibility for the payout. The 3rd Annual General Meeting (AGM) is scheduled for June 26, 2026, via video conferencing. The register of members will remain closed from June 20 to June 26, 2026, for the purpose of this dividend distribution.
Key Highlights
Record date for FY 2025 final dividend is fixed as June 19, 2026
Book closure period scheduled from June 20, 2026, to June 26, 2026
3rd Annual General Meeting (AGM) to be held on June 26, 2026, at 3:00 p.m. IST
Dividend will be paid to beneficial owners as per NSDL and CDSL records as of June 19, 2026
👀 What to Watch
Investors seeking the final dividend should ensure they hold shares in their demat accounts before the record date of June 19, 2026. Monitor the upcoming Annual Report for the specific dividend amount per share.
Sanofi Consumer Healthcare Sets June 19, 2026, as Record Date for Final Dividend
Sanofi Consumer Healthcare India Limited (SANOFICONR) has announced June 19, 2026, as the record date for determining shareholder eligibility for its final dividend for the financial year 2025. The company's 3rd Annual General Meeting (AGM) is scheduled to take place on June 26, 2026, via video conferencing. Share transfer books will remain closed from June 20 to June 26, 2026, to facilitate the dividend payment process. This corporate action follows the company's recent listing and operational updates.
Key Highlights
Record date for the final dividend is fixed as Friday, June 19, 2026.
The 3rd Annual General Meeting (AGM) will be held on Friday, June 26, 2026, at 3:00 p.m. IST.
Register of Members and Share Transfer Books will be closed from June 20, 2026, to June 26, 2026.
The dividend will be paid to shareholders whose names appear as beneficial owners at the close of business on the record date.
👀 What to Watch
Investors interested in the dividend should ensure they hold the company's shares before the ex-dividend date, typically one day prior to the June 19 record date. Shareholders should also review the upcoming Annual Report for the specific dividend amount and financial performance details.
Sanofi Consumer Healthcare India Sets June 19 as Record Date for Final Dividend
Sanofi Consumer Healthcare India Limited (SANOFICONR) has announced its 3rd Annual General Meeting (AGM) scheduled for June 26, 2026. The company has fixed June 19, 2026, as the Record Date to determine shareholder eligibility for the final dividend for the financial year 2025. The Register of Members and Share Transfer Books will remain closed from June 20 to June 26, 2026. This routine corporate action confirms the timeline for shareholder payouts following the company's recent demerger and listing processes.
Key Highlights
3rd Annual General Meeting (AGM) to be held on June 26, 2026, at 3:00 p.m. IST.
Record date for final dividend eligibility is fixed as Friday, June 19, 2026.
Book closure period for dividend and AGM is from June 20, 2026, to June 26, 2026.
The meeting will be conducted via Video Conferencing/Other Audio-Visual Means.
Final dividend payment is subject to shareholder approval at the upcoming AGM.
👀 What to Watch
Investors interested in the final dividend should ensure they hold the stock before the record date of June 19, 2026. Existing shareholders should review the upcoming Annual Report for the specific dividend amount and growth guidance.
Sanofi Consumer Healthcare Appoints PwC as Statutory Auditor for 5-Year Term
Sanofi Consumer Healthcare India Limited has appointed Price Waterhouse & Co Chartered Accountants LLP (PwC) as its new Statutory Auditor. This appointment fills the casual vacancy created by the resignation of M/s. Kalyaniwalla & Mistry LLP on April 30, 2026. The Board has also recommended PwC for a full five-year term from 2026 to 2031, subject to shareholder approval at the upcoming Annual General Meeting. The transition to a Big Four affiliate firm is typically seen as a positive step for enhancing corporate governance and financial reporting credibility.
Key Highlights
Appointment of PwC to fill casual vacancy effective May 25, 2026, until the next AGM.
Recommended 5-year term for PwC starting from the 2026 AGM through to the 2031 AGM.
The change follows the resignation of previous auditors M/s. Kalyaniwalla & Mistry LLP on April 30, 2026.
PwC India network has over 120 Assurance Partners and 17 branch offices as of April 2026.
👀 What to Watch
Investors should view the appointment of a globally recognized audit firm as a positive governance move. No immediate action is required other than noting the change for future financial reporting cycles.
Sanofi Consumer Healthcare Statutory Auditor Resigns Due to Audit Fee Dispute
M/s. Kalyaniwalla & Mistry LLP has resigned as the statutory auditor of Sanofi Consumer Healthcare India Limited, effective April 30, 2026. The firm cited the commercial unviability of continuing the audit after the company declined a requested fee increase for FY 2026. The auditors were originally appointed for a five-year term ending in 2028. Notably, the outgoing auditors confirmed there are no other material concerns or issues with obtaining audit evidence.
Key Highlights
Statutory Auditor M/s. Kalyaniwalla & Mistry LLP resigned effective April 30, 2026.
The resignation follows the company's refusal to accommodate a fee increase requested on April 25, 2026.
The auditor was in the second year of a five-year term originally scheduled to run from 2024 to 2028.
Auditor confirmed no concerns regarding financial statements or inability to obtain audit evidence.
👀 What to Watch
Investors should monitor the appointment of a successor auditor to ensure a smooth transition. While auditor resignations can be a red flag, the explicit mention of a fee dispute suggests this is a commercial disagreement rather than a sign of financial irregularity.
Sanofi Consumer Healthcare Q1 26: Revenue Up 33% to ₹2,292 MN, PAT Rises 36%
Sanofi Consumer Healthcare India (SCHIL) reported a strong Q1 2026 with total revenue reaching ₹2,292 million, a 33% year-on-year increase. Net profit for the quarter grew by 36% to ₹678 million, reflecting disciplined execution and market share gains. Domestic sales were up 15.5%, significantly aided by the relaunch of recalled products, while export sales surged 144% due to a low base effect. This performance marks a positive trajectory for the company following its demerger from Sanofi India in June 2024.
Key Highlights
Total Revenue grew 33% YoY to ₹2,292 million in Q1 2026
Net Profit (PAT) increased by 36% YoY to ₹678 million
Domestic sales grew by 15.5%, supported by product relaunches and market share gains
Export sales saw a significant 144% growth, primarily due to a low base in the previous year
Key brands like Allegra, DePURA, Avil, and Combiflam continue to drive the consumer healthcare portfolio
👀 What to Watch
The strong double-digit growth in both top-line and bottom-line suggests the demerged entity is scaling well; investors should monitor the sustainability of domestic volume growth. The successful relaunch of recalled products is a key positive catalyst for future quarters.
Sanofi Consumer Healthcare Q1 PAT Rises 35.6% YoY to ₹67.8 Cr; Revenue Up 32.8%
Sanofi Consumer Healthcare India reported a strong year-on-year performance for the quarter ended March 31, 2026, with net profit rising 35.6% to ₹678 million. Revenue from operations grew 32.8% YoY to ₹2,292 million, primarily driven by a 15.5% growth in domestic sales following the successful relaunch of key brands like Allegra and Combiflam. While YoY growth is robust, revenue saw a sequential decline of 8.7% compared to the December 2025 quarter. The company maintains healthy margins with Profit Before Tax (PBT) reaching ₹907 million.
Key Highlights
Revenue from operations increased 32.8% YoY to ₹2,292 million from ₹1,726 million.
Net Profit (PAT) grew 35.6% YoY to ₹678 million compared to ₹500 million in the year-ago period.
Domestic sales grew by 15.5% YoY, aided by the relaunch of Allegra Suspension, Combiflam Suspension, and Depura Kids.
Export sales witnessed a significant jump of 144.4% YoY, though on a lower base.
Earnings Per Share (EPS) improved to ₹29.44 from ₹21.69 in the same quarter last year.
👀 What to Watch
Investors should view the strong YoY growth as a sign of successful brand recovery following previous product recalls. The stock remains a watch for steady growth in the consumer healthcare segment, though sequential revenue dips should be monitored for seasonality.
Sanofi Consumer Healthcare Shareholders Approve Key RPTs and MD Remuneration
Sanofi Consumer Healthcare India Limited (SANOFICONR) has announced the successful passage of four key resolutions via postal ballot, all receiving over 99.9% shareholder approval. The resolutions include material related party transactions with Opella Healthcare entities and the establishment of remuneration limits for Non-Executive Directors. Crucially, shareholders approved an amendment to Managing Director Himanshu Bakshi's remuneration to enable his participation in the company's incentive plan. These approvals facilitate operational continuity and align leadership incentives with business performance.
Key Highlights
Material related party transactions with Opella Healthcare India and International SAS approved with over 99.94% votes in favor.
Remuneration limits for Non-Executive Directors passed with a near-unanimous 99.99% majority.
Amendment to MD Himanshu Bakshi's remuneration for incentive plan participation approved by 99.98% of voters.
The voting process involved 50,742 shareholders on record as of March 20, 2026.
👀 What to Watch
Investors should take note of the strong shareholder support for management's compensation structure and operational agreements. The alignment of the Managing Director's pay with incentive plans is a positive governance signal for long-term performance.
Sanofi Consumer Healthcare Reports 21% Revenue Growth and 62.5% ROCE in First Investor Meet
Sanofi Consumer Healthcare India Limited (SCHIL) detailed its strategic transition to a standalone 'Fast Moving Consumer Health' entity following its demerger. For FY2025, the company reported a turnover of approximately ₹880 crore, representing a 21% revenue growth and a 33% increase in PAT. Management is aggressively pivoting from a prescription-only model to a brand-led consumer model, increasing advertising and promotion spends from low single digits to mid-teens. The company maintains a high-quality balance sheet with an operating profit margin of 37% and a robust ROCE of 62.5%.
Key Highlights
Achieved ₹880 crore turnover with a 33% year-on-year increase in Profit After Tax (PAT).
Reported a high Return on Capital Employed (ROCE) of 62.5% and operating profit margins of 37%.
Increased brand investment (A&P) to mid-teen percentages to drive self-choice consumer growth.
Core brands like Avil, Allegra, and Combiflam maintain top 5 positions in their respective categories.
Successfully completed product relaunches following precautionary quality recalls, restoring market leadership.
👀 What to Watch
Investors should monitor the company's ability to sustain high margins while scaling marketing spends in the competitive consumer health space. The high ROCE and strong brand legacy make it a premium play in the Indian healthcare sector.
Sanofi Consumer Healthcare Reports 33% PAT Growth and Outlines 2X Reach Strategy
Sanofi Consumer Healthcare India Limited (SCHIL) reported a strong FY2025 with revenue growing 21% to ₹8,784 million and PAT increasing by 33%. The company is pivoting to a Fast Moving Consumer Healthcare (FMCH) model, aiming to double its doctor reach and direct retail coverage. With a high ROCE of 62.5% and market-leading brands like Avil and Allegra, the management is focusing on digital-first demand generation and FMCG-style talent acquisition. The strategy emphasizes scaling consumer engagement to a 60 million multi-media reach to capture high headroom in the Allergy, Pain, and Vitamin D categories.
Key Highlights
Revenue from operations grew 21% YoY to ₹8,784 million with a 36.7% operating profit margin.
Profit After Tax (PAT) increased by 33% YoY, supported by a robust 62.5% Return on Capital Employed (ROCE).
Company plans to double (2X) its doctor reach and direct retail coverage to improve market access.
Maintains strong brand equity with Avil ranked #1 in volume and Allegra ranked #3 in value within their categories.
Digital-first approach targeting 30% demand generation and a 60 million multi-media reach.
👀 What to Watch
Investors should note the company's high capital efficiency (62.5% ROCE) and its aggressive transition toward a retail-heavy FMCH model. The stock remains a strong play on the increasing consumer self-medication trend in India, though execution of the 2X reach target will be the key metric to watch.
Sanofi Consumer Healthcare Seeks Approval for ₹4,614 Million Related Party Transactions
Sanofi Consumer Healthcare India Limited has issued a postal ballot notice seeking shareholder approval for material related party transactions (RPTs) for the 2026 calendar year. The company is proposing a transaction limit of ₹1,200 million with Opella Healthcare India and ₹3,414 million with Opella Healthcare International SAS. Additionally, the ballot covers the approval of remuneration for Non-Executive Directors up to 1% of net profits and an amendment to the Managing Director's incentive plan. The e-voting period runs from March 24, 2026, to April 22, 2026.
Key Highlights
Proposed RPT limit of ₹1,200 million with Opella Healthcare India Private Limited for the year ending December 2026.
Proposed RPT limit of ₹3,414 million with Opella Healthcare International SAS for the year ending December 2026.
Approval sought for Non-Executive Director commissions not exceeding 1% of annual Net Profits.
Amendment to Managing Director Himanshu Bakshi's remuneration terms to enable participation in the company's Incentive Plan.
Voting results to be announced on or before April 24, 2026, following the month-long e-voting window.
👀 What to Watch
Investors should monitor the outcome of the vote to ensure that the significant related party transactions are conducted at arm's length and do not adversely affect minority interests. The scale of these transactions reflects the company's operational integration with the global Opella/Sanofi structure.
Sanofi Consumer Healthcare Q4 Profit Jumps 50% to ₹665 MN; ₹75 Dividend Declared
Sanofi Consumer Healthcare India (SCHIL) reported a robust Q4 performance with revenue growing 47% YoY to ₹2,510 million and net profit surging 50% to ₹665 million. For the full year 2025, the company achieved a 21% revenue growth and a 33% increase in PAT, reaching ₹2,401 million. The board has recommended a substantial dividend of ₹75 per share, reflecting strong cash generation. Growth was primarily driven by a 23% rise in domestic sales and the successful relaunch of recalled products.
Key Highlights
Q4 Revenue grew 47% YoY to ₹2,510 million, while Net Profit rose 50% to ₹665 million.
Full-year FY25 PAT increased by 33% to ₹2,401 million on total revenue of ₹8,784 million.
Declared a significant dividend of ₹75 per share for the financial year ended December 31, 2025.
Domestic sales grew by 23% in Q4, supported by brand relaunches and core portfolio strength.
Export sales for Q4 grew 9.3x and full-year exports grew 158%, albeit from a low base.
👀 What to Watch
The strong double-digit growth and high dividend payout indicate successful post-demerger stabilization and operational efficiency. Investors may consider this a positive signal for long-term value in the consumer healthcare space, given the strength of brands like Combiflam and Allegra.
Sanofi Consumer Healthcare FY25 Net Profit Jumps 33% to ₹240 Cr; Recommends ₹75 Dividend
Sanofi Consumer Healthcare India reported a strong financial performance for the year ended December 31, 2025, with annual revenue growing 21% to ₹8,784 million. Net profit for the full year surged by 32.6% to ₹2,401 million, driven by robust operational performance and higher other income. The Board has recommended a substantial final dividend of ₹75 per equity share, highlighting strong cash flow generation. Quarterly growth was even more pronounced, with Q4 revenue increasing 47% year-on-year to ₹2,510 million.
Key Highlights
Full-year FY25 revenue increased 21.2% to ₹8,784 million from ₹7,245 million in FY24.
Net profit for FY25 rose to ₹2,401 million, up from ₹1,810 million in the previous year.
Board recommended a final dividend of ₹75 per equity share (750% of face value).
Earnings Per Share (EPS) for FY25 improved significantly to ₹104.27 from ₹78.59.
Q4 FY25 net profit stood at ₹665 million, a 50% increase compared to ₹443 million in Q4 FY24.
👀 What to Watch
Investors should view these results positively given the strong double-digit growth in both top-line and bottom-line, coupled with a high dividend payout. The stock remains attractive for those seeking a combination of growth in the consumer healthcare space and high yield.
Sanofi Consumer Healthcare Recommends Rs 75 Dividend; FY25 Net Profit Rises 33%
Sanofi Consumer Healthcare India has recommended a final dividend of Rs. 75 per share for the financial year ended December 31, 2025. The company reported a strong financial performance with annual revenue growing 21% to Rs. 8,784 million. Net profit for the full year increased significantly by 33% to Rs. 2,401 million compared to the previous year. The quarterly performance was also robust, with Q4 profit rising to Rs. 665 million from Rs. 443 million year-on-year.
Key Highlights
Recommended a final dividend of Rs. 75 per equity share of face value Rs. 10.
Annual Revenue from Operations grew 21.2% YoY to Rs. 8,784 million in FY25.
Net Profit for the full year surged 32.7% to Rs. 2,401 million from Rs. 1,810 million.
Earnings Per Share (EPS) increased to Rs. 104.27 from Rs. 78.59 in the previous year.
Q4 FY25 revenue stood at Rs. 2,510 million, a 47% increase over Q4 FY24.
👀 What to Watch
Investors should note the strong growth trajectory and the substantial dividend payout which reflects robust cash flows. The stock is likely to be viewed favorably by both growth and income-seeking investors due to the earnings outperformance.
Sanofi Consumer Healthcare FY25 Net Profit Jumps 33% to ₹2,401 Mn; ₹75/Share Dividend Declared
Sanofi Consumer Healthcare India reported a strong performance for the financial year ended December 31, 2025, with annual revenue growing 21% to ₹8,784 million. Net profit for the full year increased significantly by 32.6% to ₹2,401 million, supported by improved operational efficiencies. The Board has recommended a substantial final dividend of ₹75 per share, reflecting a high payout ratio and strong cash position. Quarterly performance was also robust, with Q4 revenue up 47% year-on-year to ₹2,510 million.
Key Highlights
Full-year FY25 Revenue from Operations rose 21.2% YoY to ₹8,784 million versus ₹7,245 million.
Net Profit for FY25 increased to ₹2,401 million from ₹1,810 million in the previous year.
Recommended a final dividend of ₹75 per equity share of face value ₹10 for the financial year.
Q4 FY25 Net Profit grew 50% YoY to ₹665 million compared to ₹443 million in Q4 FY24.
Earnings Per Share (EPS) improved significantly to ₹104.27 for FY25 from ₹78.59 in FY24.
👀 What to Watch
Investors should react positively to the strong double-digit growth in both revenue and profitability alongside a very generous dividend payout. The company's transition and focus on consumer healthcare appear to be yielding high margins and robust cash flows.
